Mersana Therapeutics, Inc. (MRSN)
- Previous Close
2.8500 - Open
2.8400 - Bid 2.9100 x 800
- Ask 2.9400 x 800
- Day's Range
2.7800 - 2.9575 - 52 Week Range
0.8010 - 9.6200 - Volume
851,384 - Avg. Volume
2,217,498 - Market Cap (intraday)
356.631M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4800 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.71
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
www.mersana.comRecent News: MRSN
Performance Overview: MRSN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRSN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRSN
Valuation Measures
Market Cap
356.63M
Enterprise Value
181.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.26
Price/Book (mrq)
9.66
Enterprise Value/Revenue
4.92
Enterprise Value/EBITDA
-1.09
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.13%
Return on Equity (ttm)
-266.24%
Revenue (ttm)
36.85M
Net Income Avi to Common (ttm)
-171.67M
Diluted EPS (ttm)
-1.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
209.08M
Total Debt/Equity (mrq)
91.67%
Levered Free Cash Flow (ttm)
-85.71M